New biomarkers: prospect for diagnosis and monitoring of thyroid disease
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
After the metabolic syndrome and its components, thyroid disorders represent the most common endocrine disorders, with increasing prevalence in the last two decades. Thyroid dysfunctions are distinguished by hyperthyroidism, hypothyroidism, or inflammation (thyroiditis) of the thyroid gland, in addition to the presence of thyroid nodules that can be benign or malignant. Thyroid cancer is typically detected via an ultrasound (US)-guided fine-needle aspiration biopsy (FNAB) and cytological examination of the specimen. This approach has significant limitations due to the small sample size and inability to characterize follicular lesions adequately. Due to the rapid advancement of high-throughput molecular biology techniques, it is now possible to identify new biomarkers for thyroid neoplasms that can supplement traditional imaging modalities in postoperative surveillance and aid in the preoperative cytology examination of indeterminate or follicular lesions. Here, we review current knowle...dge regarding biomarkers that have been reliable in detecting thyroid neoplasms, making them valuable tools for assessing the efficacy of surgical procedures or adjunctive treatment after surgery. We are particularly interested in providing an up-to-date and systematic review of emerging biomarkers, such as mRNA and non-coding RNAs, that can potentially detect thyroid neoplasms in clinical settings. We discuss evidence for miRNA, lncRNA and circRNA dysregulation in several thyroid neoplasms and assess their potential for use as diagnostic and prognostic biomarkers.
Кључне речи:
biomarkers / circRNA / lncRNA / miRNA / mRNA / non-coding RNAs / thyroid cancer / thyroid disordersИзвор:
Frontiers in Endocrinology, 2023, 14, 1218320-Финансирање / пројекти:
- Министарство науке, технолошког развоја и иновација Републике Србије, институционално финансирање - 200017 (Универзитет у Београду, Институт за нуклеарне науке Винча, Београд-Винча) (RS-MESTD-inst-2020-200017)
- King Abdullah University of Science and Technology (KAUST) [BAS/1/1624-01-01]
- King Abdullah University of Science and Technology (KAUST) [FCC/1/1976-47-01]
- King Abdullah University of Science and Technology (KAUST) [FCC/1/1976-26-01]
- King Abdullah University of Science and Technology (KAUST) [URF/1/3450-01-01]
- King Abdullah University of Science and Technology (KAUST) [REI/1/4216-01-01]
- King Abdullah University of Science and Technology (KAUST) [REI/1/4437-01-01]
- King Abdullah University of Science and Technology (KAUST) [REI/1/4473-01-01]
- King Abdullah University of Science and Technology (KAUST) [URF/1/4098-01-01]
DOI: 10.3389/fendo.2023.1218320
ISSN: 1664-2392
PubMed: 37547301
WoS: 001040386400001
Scopus: 2-s2.0-85167331176
Колекције
Институција/група
VinčaTY - JOUR AU - Mačvanin, Mirjana AU - Gluvić, Zoran AU - Zarić, Božidarka AU - Essack, Magbubah AU - Gao, Xin AU - Isenović, Esma R. PY - 2023 UR - https://vinar.vin.bg.ac.rs/handle/123456789/11405 AB - After the metabolic syndrome and its components, thyroid disorders represent the most common endocrine disorders, with increasing prevalence in the last two decades. Thyroid dysfunctions are distinguished by hyperthyroidism, hypothyroidism, or inflammation (thyroiditis) of the thyroid gland, in addition to the presence of thyroid nodules that can be benign or malignant. Thyroid cancer is typically detected via an ultrasound (US)-guided fine-needle aspiration biopsy (FNAB) and cytological examination of the specimen. This approach has significant limitations due to the small sample size and inability to characterize follicular lesions adequately. Due to the rapid advancement of high-throughput molecular biology techniques, it is now possible to identify new biomarkers for thyroid neoplasms that can supplement traditional imaging modalities in postoperative surveillance and aid in the preoperative cytology examination of indeterminate or follicular lesions. Here, we review current knowledge regarding biomarkers that have been reliable in detecting thyroid neoplasms, making them valuable tools for assessing the efficacy of surgical procedures or adjunctive treatment after surgery. We are particularly interested in providing an up-to-date and systematic review of emerging biomarkers, such as mRNA and non-coding RNAs, that can potentially detect thyroid neoplasms in clinical settings. We discuss evidence for miRNA, lncRNA and circRNA dysregulation in several thyroid neoplasms and assess their potential for use as diagnostic and prognostic biomarkers. T2 - Frontiers in Endocrinology T1 - New biomarkers: prospect for diagnosis and monitoring of thyroid disease VL - 14 SP - 1218320 DO - 10.3389/fendo.2023.1218320 ER -
@article{ author = "Mačvanin, Mirjana and Gluvić, Zoran and Zarić, Božidarka and Essack, Magbubah and Gao, Xin and Isenović, Esma R.", year = "2023", abstract = "After the metabolic syndrome and its components, thyroid disorders represent the most common endocrine disorders, with increasing prevalence in the last two decades. Thyroid dysfunctions are distinguished by hyperthyroidism, hypothyroidism, or inflammation (thyroiditis) of the thyroid gland, in addition to the presence of thyroid nodules that can be benign or malignant. Thyroid cancer is typically detected via an ultrasound (US)-guided fine-needle aspiration biopsy (FNAB) and cytological examination of the specimen. This approach has significant limitations due to the small sample size and inability to characterize follicular lesions adequately. Due to the rapid advancement of high-throughput molecular biology techniques, it is now possible to identify new biomarkers for thyroid neoplasms that can supplement traditional imaging modalities in postoperative surveillance and aid in the preoperative cytology examination of indeterminate or follicular lesions. Here, we review current knowledge regarding biomarkers that have been reliable in detecting thyroid neoplasms, making them valuable tools for assessing the efficacy of surgical procedures or adjunctive treatment after surgery. We are particularly interested in providing an up-to-date and systematic review of emerging biomarkers, such as mRNA and non-coding RNAs, that can potentially detect thyroid neoplasms in clinical settings. We discuss evidence for miRNA, lncRNA and circRNA dysregulation in several thyroid neoplasms and assess their potential for use as diagnostic and prognostic biomarkers.", journal = "Frontiers in Endocrinology", title = "New biomarkers: prospect for diagnosis and monitoring of thyroid disease", volume = "14", pages = "1218320", doi = "10.3389/fendo.2023.1218320" }
Mačvanin, M., Gluvić, Z., Zarić, B., Essack, M., Gao, X.,& Isenović, E. R.. (2023). New biomarkers: prospect for diagnosis and monitoring of thyroid disease. in Frontiers in Endocrinology, 14, 1218320. https://doi.org/10.3389/fendo.2023.1218320
Mačvanin M, Gluvić Z, Zarić B, Essack M, Gao X, Isenović ER. New biomarkers: prospect for diagnosis and monitoring of thyroid disease. in Frontiers in Endocrinology. 2023;14:1218320. doi:10.3389/fendo.2023.1218320 .
Mačvanin, Mirjana, Gluvić, Zoran, Zarić, Božidarka, Essack, Magbubah, Gao, Xin, Isenović, Esma R., "New biomarkers: prospect for diagnosis and monitoring of thyroid disease" in Frontiers in Endocrinology, 14 (2023):1218320, https://doi.org/10.3389/fendo.2023.1218320 . .